Gregory Fraser
Stock Analyst at Truist Securities
(3.32)
# 846
Out of 4,818 analysts
36
Total ratings
51.85%
Success rate
14.79%
Average return
Main Sectors:
Stocks Rated by Gregory Fraser
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ANIP ANI Pharmaceuticals | Maintains: Hold | $62 → $65 | $68.37 | -4.93% | 9 | Apr 21, 2025 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Buy | $220 → $230 | $104.19 | +120.75% | 1 | Mar 6, 2025 | |
| BHC Bausch Health Companies | Maintains: Hold | $8 → $7 | $5.17 | +35.40% | 2 | Jul 25, 2024 | |
| XAIR Beyond Air | Maintains: Buy | $10 → $8 | $0.21 | +3,762.87% | 6 | Apr 30, 2024 | |
| BTMD biote | Maintains: Buy | $10 → $9 | $3.47 | +159.37% | 2 | Jan 18, 2024 | |
| AMRX Amneal Pharmaceuticals | Maintains: Buy | $6 → $7 | $7.30 | -4.11% | 4 | Nov 8, 2023 | |
| CORT Corcept Therapeutics | Maintains: Hold | $26 → $29 | $69.27 | -58.13% | 5 | Aug 3, 2023 | |
| NVCR NovoCure | Reiterates: Buy | $95 | $17.70 | +436.87% | 3 | Jun 6, 2023 | |
| EOLS Evolus | Maintains: Buy | $14 → $18 | $11.25 | +60.00% | 2 | May 26, 2023 | |
| ARQT Arcutis Biotherapeutics | Maintains: Buy | $45 → $40 | $14.45 | +176.82% | 2 | May 26, 2023 |
ANI Pharmaceuticals
Apr 21, 2025
Maintains: Hold
Price Target: $62 → $65
Current: $68.37
Upside: -4.93%
Jazz Pharmaceuticals
Mar 6, 2025
Maintains: Buy
Price Target: $220 → $230
Current: $104.19
Upside: +120.75%
Bausch Health Companies
Jul 25, 2024
Maintains: Hold
Price Target: $8 → $7
Current: $5.17
Upside: +35.40%
Beyond Air
Apr 30, 2024
Maintains: Buy
Price Target: $10 → $8
Current: $0.21
Upside: +3,762.87%
biote
Jan 18, 2024
Maintains: Buy
Price Target: $10 → $9
Current: $3.47
Upside: +159.37%
Amneal Pharmaceuticals
Nov 8, 2023
Maintains: Buy
Price Target: $6 → $7
Current: $7.30
Upside: -4.11%
Corcept Therapeutics
Aug 3, 2023
Maintains: Hold
Price Target: $26 → $29
Current: $69.27
Upside: -58.13%
NovoCure
Jun 6, 2023
Reiterates: Buy
Price Target: $95
Current: $17.70
Upside: +436.87%
Evolus
May 26, 2023
Maintains: Buy
Price Target: $14 → $18
Current: $11.25
Upside: +60.00%
Arcutis Biotherapeutics
May 26, 2023
Maintains: Buy
Price Target: $45 → $40
Current: $14.45
Upside: +176.82%